Quintrio
Home

PHARMACEUTICAL PREPARATIONS

XBiotech Inc

XBIT

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Last trade $1.79
Day change -$0.06 (-3.24%)
Day range $1.79 – $1.87
Volume 41,777
Market cap $56M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$56.4M
Price / earnings
—
Price / book
0.45×
Price / sales
—
EV / sales
—
EV / EBITDA
1.05×

Profitability

Earnings per share
-$1.43
Return on assets
-33.89%
Return on equity
-35.13%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
39.51×
Quick ratio
39.51×
Cash ratio
39.02×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$41M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for XBIT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$663K$850K$1.07M$4.4M$967K$1M$1.93M$927K
Research and development$4.66M$5.3M$5.21M$25.36M$5.08M$5.34M$11.62M$7.82M
Total operating expenses$5.32M$6.15M$6.27M$29.76M$6.05M$6.34M$13.55M$8.75M
Operating income-$5.32M-$6.15M-$6.27M-$29.76M-$6.05M-$6.34M-$13.55M-$8.75M
Interest expense$0$0$0$0$0$0-$88K$0
Income before taxes-$4.43M-$6.68M-$5.46M-$26.82M-$5.91M-$1.73M-$10.86M-$10.55M
Income taxes$35K$46K$49K$76K$102K$28K$29K-$41K
Net income-$4.46M-$6.73M-$5.51M-$26.89M-$6.01M-$1.76M-$10.88M-$10.51M
Net income attributable to common shareholders-$4.46M-$6.73M-$5.51M-$26.89M-$6.01M-$1.76M-$10.88M-$10.51M
EBITDA-$5.07M-$5.84M-$5.94M-$29.38M-$5.62M-$5.9M-$13.11M-$8.31M
Basic earnings per share-$0.15-$0.22-$0.18-$0.88-$0.20-$0.06-$0.36-$0.34
Diluted earnings per share-$0.15-$0.22-$0.18-$0.88-$0.20-$0.06-$0.36-$0.34

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

XBiotech annonce la nomination de Sushma Shivaswamy et Jan-Paul Simard aux postes de co-directeurs généraux

XBiotech Inc. (NASDAQ: XBIT) announced the appointment of Jan-Paul Simard as Co-Chief Executive Officer alongside Dr. Sushma Shivaswamy, effective October 23, 2026. Dr. Shivaswamy, who has been with the company for 17 years and served as interim CEO following the founder's retirement, will now share leadership responsibilities with Simard, who joined XBiotech in 2012 and has contributed to clinical trial development across multiple therapeutic areas.

GlobeNewswire Inc.

XBiotech gibt die Wahl von Sushma Shivaswamy und Jan-Paul Simard zu Co-Chief Executive Officers bekannt

XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside Dr. Sushma Shivaswamy, effective October 23, 2026. Dr. Shivaswamy, who has been with the company for 17 years and served as Interim CEO since December 2025, will now share leadership responsibilities with Simard. The co-CEO structure aims to leverage their complementary skills and scientific expertise to advance the company's true Human antibody therapies across oncology, inflammatory diseases, and infectious diseases.

GlobeNewswire Inc.

XBiotech annonce des résultats d’efficacité finaux positifs de phase II pour l’essai TASKIN commandité par un chercheur dans le cancer colorectal métastatique réfractaire

XBiotech announced positive Phase II results for its anti-IL-1α monoclonal antibody vilamakitug (Natrunix) in treating refractory metastatic colorectal cancer. The investigator-sponsored TASKIN trial met its primary efficacy endpoint with 61.3% 12-month overall survival in the treatment arm versus 55.7% in the control arm. Notably, exploratory analysis showed a statistically significant 62% reduction in death risk for right-sided colon tumors, a historically aggressive subtype with high unmet medical needs.

GlobeNewswire Inc.

XBiotech gibt positive endgültige Wirksamkeitsergebnisse der Phase-II-Studie „TASKIN“ bekannt, einer von Forschern initiierten Studie zur Behandlung von refraktärem metastasiertem Kolorektalkarzinom

XBiotech announced positive final efficacy results from the Phase II TASKIN trial of its anti-IL-1α monoclonal antibody Vilamakitug (XB2001) combined with standard chemotherapy for refractory metastatic colorectal cancer. The study met its primary efficacy endpoint with a 12-month overall survival rate of 61.3% versus 55.7% in the control group. An exploratory subgroup analysis showed a statistically significant 62% reduction in mortality risk for patients with right-sided tumors.

GlobeNewswire Inc.

XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

XBiotech announced positive Phase II results from the TASKIN trial showing its anti-IL-1α monoclonal antibody vilamakitug (XB2001) met primary efficacy criteria with 61.3% 12-month overall survival in refractory metastatic colorectal cancer patients. An exploratory analysis revealed significant survival benefits in right-sided tumors, with a 62% reduction in death risk compared to control.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Jul 15, 2021$2.0995Jul 23, 2021special

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.